Please provide your email address to receive an email when new articles are posted on . Weekly injectable is first new treatment for candidemia and invasive candidiasis in more than a decade. Rezzayo ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Recurrent candidemia was reported in 6% of people with ...

Candidemia is uncommon following solid organ transplantation but carries a high mortality risk, necessitating targeted prevention strategies. Candidemia occurs infrequently after solid organ ...

Candida is one of the most common causes of nosocomial bloodstream infections. Candidemia is not confined to hematological patients, intensive care units or abdominal surgery wards, but it is ...

This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major ...

Credit: Melinta Therapeutics. Rezzayo is supplied as a solid (cake or powder) in a single-dose vial containing 200mg of rezafungin. Rezzayo ™ (rezafungin for injection) is now available for the ...

Credit: Getty Images. Rezafungin is an investigational echinocandin antifungal that is administered once weekly. The Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee voted ...

Candida infections cause substantial morbidity and mortality in neonates. Persistent candidemia has not been associated with increased risk of mortality compared with candidemia of shorter duration.

An FDA advisory committee on Tuesday overwhelmingly recommended approval, with a "limited use" indication, of long-acting rezafungin for the treatment of candidemia and invasive candidiasis (IC) in ...

Expert Rev Clin Immunol. 2012;8(8):755-765. Different strategies can be used for managing suspected or documented candidemia, including prophylaxis, empirical or pre-emptive therapy and treatment of a ...